Barbara Jonchere

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 3

Top Topics

Dna Damage Response

Top Venues

Molecular cancer therapeutics

Cancer research

This page only lists publications with an associated author ORCID identifier.

Publications

Martine F Roussel, Barbara Jonchere, Justin S Williams, Frederique Zindy, JingJing Liu, Sarah Robinson, Dana M Farmer, Jaeki Min, Lei Yang, Jennifer L Stripay, Yingzhe Wang, Burgess B Freeman, Jiyang Yu, Anang A Shelat, Zoran Rankovic
Combination of ribociclib with BET-bromodomain and PI3K/mTOR inhibitors for medulloblastoma treatment in vitro and in vivo. Molecular cancer therapeutics (2022)
Allison Pribnow, Barbara Jonchere, JingJing Liu, Kyle S Smith, Olivia Campagne, Ke Xu, Sarah Robinson, Yogesh Patel, Arzu Onar-Thomas, Gang Wu, Clinton F Stewart, Paul A Northcott, Jiyang Yu, Giles W Robinson, Martine F Roussel
Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma. Molecular cancer therapeutics 21 (8) (2022)
P Jake Slavish, Liying Chi, Mi-Kyung Yun, Lyudmila Tsurkan, Nancy E Martinez, Barbara Jonchere, Sergio C Chai, Michele Connelly, M Brett Waddell, Sourav Das, Geoffrey A Neale, Zhenmei Li, William R Shadrick, Rachelle R Olsen, Kevin W Freeman, Jonathan A Low, Jeanine E Price, Brandon M Young, Nagakumar Bharatham, Vincent A Boyd, Jun Yang, Richard E Lee, Marie Morfouace, Martine F Roussel, Taosheng Chen, Daniel Savic, R Kiplin Guy, Stephen W White, Anang A Shelat, Philip M Potter
Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer. Cancer research 80 (17) (2020)